NEW YORK (GenomeWeb) — Horizon Discovery Group said today that it has entered into an original equipment manufacturer agreement with CareDx.
Under the agreement, Horizon will supply cell-free DNA-based molecular reference standards for inclusion in CareDx's cfDNA testing workflows for the monitoring of transplanted organ rejection. Financial details of the agreement were not disclosed.
The agreement is an extension of a previously announced collaboration for the development of cell-free reference standards to support proficiency testing of CareDx's solid organ transplant injury monitoring test, AlloSure. The companies expect to forge future similar agreements, Horizon said.
"The inclusion of Horizon's reference standards as a routine tool used by CareDx demonstrates that Horizon is becoming a trusted provider of controls in the liquid biopsy space, and that they are equally valuable for applications beyond oncology," Horizon CEO Darrin Disley said in a statement. "This agreement further validates Horizon's strategy of entering into early development programmes with assay service providers and kit vendors, and working closely with them to forge long-term relationships and establish ongoing OEM-based revenue streams."